EUPATI Launch Meeting, 27 March 2012, Copenhagen: Presentation of Michel Goldman, IMI

1. The Innovative Medicines Initiative:
Promoting patient involvement
in drug development
Michel Goldman, MD, PhD
Executive Director
EUPATI Launch, Copenhagen, 27 March 2012

2. Innovative Medicines Initiative:
Joining public and private forces
2 Billion Euro
1 Billion € 1 Billion €
Public Private
Partnership

3. Core objectives
• To overcome research bottlenecks in drug
development through collaborative approaches
• To increase investments in the biopharmaceutical
sector and provide socio-economic benefits across
Europe
• To contribute to the health of European citizens

4. Key concepts
• Non-competitive research for EFPIA companies
• Competitive calls for IMI beneficiaries
• Open collaboration in public-private consortia

5. Major project deliverables
• Patient-reported outcomes
• Predicting biomarkers
• Novel approaches to drug safety
• Innovative tools for translational research

6. PRO-ACTIVE
Patient reported outcomes in chronic
obstructive pulmonary disease
Activity Monitoring
PDA for PROs
Physical activity
Symptoms reported
Time (days)

7. U-BIOPRED
Towards a new taxonomy of asthma
Paves the way towards tailored treatments for
asthmatic patients
38 Partners
- 9 EFPIA companies
- 23 Academic institutions
- 3 Patients’ organizations
- 3 SMEs
First achievements
 A new stepwise algorithm for the stratification
of patients with severe asthma
Thorax, 66: 910-7 (2011)

8. Clinical Pharmacology & Therapeutics March 2012,
http://www.nature.com/doifinder/10.1038/clpt.2011.321

9. Nature Medicine 18:341,
2012

10. www.imi.europa.eu
THANK YOU !